Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Total Assets : ¥9,610 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Total Assets?

Shenzhenlubris Pharmaceuticals Co's Total Assets for the quarter that ended in Mar. 2024 was ¥9,610 Mil.

During the past 12 months, Shenzhenlubris Pharmaceuticals Co's average Total Assets Growth Rate was 16.00% per year. During the past 3 years, the average Total Assets Growth Rate was 10.50% per year. During the past 5 years, the average Total Assets Growth Rate was 3.00% per year. During the past 10 years, the average Total Assets Growth Rate was 8.20% per year.

During the past 13 years, Shenzhenlubris Pharmaceuticals Co's highest 3-Year average Total Assets Growth Rate was 74.00%. The lowest was -3.70%. And the median was 17.80%.

Total Assets is connected with ROA %. Shenzhenlubris Pharmaceuticals Co's annualized ROA % for the quarter that ended in Mar. 2024 was 8.43%. Total Assets is also linked to Revenue through Asset Turnover. Shenzhenlubris Pharmaceuticals Co's Asset Turnover for the quarter that ended in Mar. 2024 was 0.11.

Shenzhenlubris Pharmaceuticals Co Total Assets Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Total Assets Chart

Shenzhenlubris Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

7,733.30

6,933.83

9,243.89

9,755.27

9,396.67

Shenzhenlubris Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															9,670.53	9,502.04	9,429.69	9,396.67	9,610.06

Shenzhenlubris Pharmaceuticals Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Shenzhenlubris Pharmaceuticals Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	8055.426	+	1341.246
	=	9,397

Shenzhenlubris Pharmaceuticals Co's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	8262.255	+	1347.802
	=	9,610

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Total Assets Explanation

Total Assets is connected with ROA %.

Shenzhenlubris Pharmaceuticals Co's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	801.06	/	( (9396.673	+	9610.056)	/ 2 )
	=	801.06	/	9503.3645
	=	8.43 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Shenzhenlubris Pharmaceuticals Co's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	1090.969	/	( (9396.673	+	9610.056)	/ 2 )
=	1090.969	/	9503.3645
=	0.11

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Shenzhenlubris Pharmaceuticals Co Total Assets Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN

Website

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.

Executives

Yan Jie	Directors, executives
Yang Jian Feng	Secretary, Director
Zhao Song Ping	Executives
Liu Jun	Executives
Li Ai Zhen	Supervisors
Chen Ping	Executives
Ye Cheng Hai	Director
Lu Feng	Executives, directors
Chen Qiong Xing	Supervisors
Li Ying Hui	Supervisors
Pan Ling Man	Independent director
Zhang Zhong Xing	Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines